Pancreatic cancer patient Ben Sasse sees 'massive' tumor reduction with experimental new drug

Cancer News Pancreatic cancer patient Ben Sasse sees 'massive' tumor reduction with experimental new drug Former senator calls experimental drug daraxonrasib a ‘miracle’ medication By Melissa Rudy Fox News Published April 28, 2026 7:00am EDT | Updated April 28, 2026 7:03am EDT Facebook Twitter Threads Flipboard Comments Print Email Add Fox News on Google close Video Former Sen. Ben Sasse vows to fight after stage 4 pancreatic cancer diagnosis Dr. Nicole Saphier discusses former Sen. Ben Sasse’s, R-Neb., stage 4 pancreatic cancer diagnosis, new immunotherapy advances and what to know as flu season ramps up. NEWYou can now listen to Fox News articles! Months after revealing his stage 4 cancer diagnosis, former U.S. Sen. Ben Sasse is speaking out about an experimental therapy that could extend his life. if (window && window.foxstrike && Array.isArray(window.foxstrike.cmd)) { window.foxstrike.cmd.push(function(Strike) { Strike.insertAd('tablet', 'lb2', 'tablet-tw-ad-lb2', ''); }); } else { console.error('Error: window.foxstrike not found'); } if (window && window.foxstrike && Array.isArray(window.foxstrike.cmd)) { window.foxstrike.cmd.push(function(Strike) { Strike.insertAd('mobile', 'ban1', 'mobile-mw-ad-ban1', ''); }); } else { console.error('Error: window.foxstrike not found'); } Sasse, a Republican who represented Nebraska between 2015 and 2023, shared in December 2025 that he has metastatic pancreatic cancer, which has spread to multiple organs — including his liver and lungs.After initially being given three to four months to live, Sasse, 54, entered a clinical trial for a drug called daraxonrasib, an oral therapy (pill) that is designed to block the defective gene that triggers uncontrolled cellular growth. if (window && window.foxstrike && Array.isArray(window.foxstrike.cmd)) { window.foxstrike.cmd.push(function(Strike) { Strike.insertAd('desktop', 'lb2', 'desktop-desk-ad-lb2', ''); }); } else { console.error('Error: window.foxstrike not found'); } CANCER SURVIVAL APPEARS TO DOUBLE WITH COMMON VACCINE, RESEARCHERS SAY if (window && window.foxstrike && Array.isArray(window.foxstrike.cmd)) { window.foxstrike.cmd.push(function(Strike) { Strike.insertAd('mobile', 'ban2', 'mobile-mw-ad-ban2', ''); }); } else { console.error('Error: window.foxstrike not found'); } The California-based drugmaker, Revolution Medicines, recently shared data from a phase 3 clinical trial of people with metastatic pancreatic cancer who did not respond to standard chemotherapy. if (window && window.foxstrike && Array.isArray(window.foxstrike.cmd)) { window.foxstrike.cmd.push(function(Strike) { Strike.insertAd('tablet', 'lb3', 'tablet-tw-ad-lb3', ''); }); } else { console.error('Error: window.foxstrike not found'); } Patients on the treatment lived a median of 13 months, compared to around six months for those who continued with chemo. Former Sen. Ben Sasse of Nebraska entered a clinical trial for a drug called daraxonrasib, an oral therapy (pill) that is designed to block the defective gene that triggers uncontrolled cellular growth. (Anna Moneymaker/Getty Images)"I have much, much less pain than I had four months ago when I was diagnosed, and I have a massive 76% reduction in tumor volume over the last four months," Sasse told "60 Minutes" in a recent interview. if (window && window.foxstrike && Array.isArray(window.foxstrike.cmd)) { window.foxstrike.cmd.push(function(Strike) { Strike.insertAd('mobile', 'ban3', 'mobile-mw-ad-ban3', ''); }); } else {…

This excerpt is published under fair use for community discussion. Read the full article at Fox News.